Wagner Baetas-Da-Cruz

Wagner Baetas-Da-Cruz

Auto-generated profile, based on publicly available information

Wagner Baetas-Da-Cruz

Postgraduate Program in Surgical Science, Department of Surgery, School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Neuroscience Research
Verified
Journal Article
Closed access
HMHugo Macedo-Ramos
Hugo Macedo-Ramos
FCFernanda S.O. Campos
Fernanda S.O. Campos
LCLitia Alves de Carvalho
Litia Alves de Carvalho
Isabela RamosIsabela Ramos
Isabela Ramos
LTLucia M. Teixeira
Lucia M. Teixeira
WBWagner Baetas-Da-Cruz
Wagner Baetas-Da-Cruz

13 December 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Sk Sarif HassanSk Sarif Hassan
Sk Sarif Hassan
SGShinjini Ghosh
Shinjini Ghosh
DADiksha Attrish
Diksha Attrish
PCPabitra Pal Choudhury
Pabitra Pal Choudhury
Alaa A. A. AljabaliAlaa A. A. Aljabali
Alaa A. A. Aljabali
ABAdam Brufsky
Adam Brufsky
Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that is engendering the severe coronavirus disease 2019 (COVID-19) pandemic. The spike (S) protein receptor-binding domain (RBD) of SARS-CoV-2 binds to the three sub-domains viz. amino acids (aa) 22–42, aa 79–84, and aa 330–393 of ACE2 on human cells to initiate entry. It was reported earlier that the receptor utilization capacity of ACE2 proteins from different species, such as cats, chimpanzees, dogs, and cattle, are different. A comprehensive analysis of ACE2 receptors of nineteen species was carried out in this study, and the findings propose a possible SARS-CoV-2 transmission flow across these nineteen species.

1 May 2012 in Brain Research
Verified
Journal Article
Closed access
AGArthur Giraldi-Guimarães
Arthur Giraldi-Guimarães
HFHelder Teixeira de Freitas
Helder Teixeira de Freitas
BCBárbara de Paula Coelho
Bárbara de Paula Coelho
HMHugo Macedo-Ramos
Hugo Macedo-Ramos
RMRosalia Mendez-Otero
Rosalia Mendez-Otero
WBWagner Baetas-Da-Cruz
Wagner Baetas-Da-Cruz

13 July 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
Kenneth LundstromKenneth Lundstrom
Kenneth Lundstrom
Debmalya BarhDebmalya Barh
Debmalya Barh
BUBruce Uhal
Bruce Uhal
KTKazuo Takayama
Kazuo Takayama
Alaa A. A. AljabaliAlaa A. A. Aljabali
Alaa A. A. Aljabali
Vladimir N. UverskyVladimir N. Uversky
Vladimir N. Uversky
Two adenovirus-based vaccines, ChAdOx1 nCoV-19 and Ad26.COV2.S, and two mRNA-based vaccines, BNT162b2 and mRNA.1273, have been approved by the European Medicines Agency (EMA), and are invaluable in preventing and reducing the incidence of coronavirus disease-2019 (COVID-19). Recent reports have pointed to thrombosis with associated thrombocytopenia as an adverse effect occurring at a low frequency in some individuals after vaccination. The causes of such events may be related to SARS-CoV-2 spike protein interactions with different C-type lectin receptors, heparan sulfate proteoglycans (HSPGs) and the CD147 receptor, or to different soluble splice variants of the spike protein, adenovirus vector interactions with the CD46 receptor or platelet factor 4 antibodies. Similar findings have been reported for several viral diseases after vaccine administration. In addition, immunological mechanisms elicited by viral vectors related to cellular delivery could play a relevant role in individuals with certain genetic backgrounds. Although rare, the potential COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) requires immediate validation, especially in risk groups, such as the elderly, chronic smokers, and individuals with pre-existing incidences of thrombocytopenia; and if necessary, a reformulation of existing vaccines.

1 June 2009 in Journal of the Peripheral Nervous System
Verified
Journal Article
Closed access
PDF file
WBWagner Baetas‐Da‐Cruz
Wagner Baetas‐Da‐Cruz
LALucineia Alves
Lucineia Alves
MPMaria Cristina V. Pessolani
Maria Cristina V. Pessolani
HBHelene S. Barbosa
Helene S. Barbosa
ARAnne Régnier‐Vigouroux
Anne Régnier‐Vigouroux
LCLeny A. Cavalcante
Leny A. Cavalcante

2 August 2014 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
HMHugo Macedo-Ramos
Hugo Macedo-Ramos
ABAndre F Batista
Andre F Batista
ACAlvaro Carrier-Ruiz
Alvaro Carrier-Ruiz
LALucineia Alves
Lucineia Alves
SASilvana Allodi
Silvana Allodi
WBWagner Baetas-Da-Cruz
Wagner Baetas-Da-Cruz
The ability of S. pneumoniae to generate infections depends on the restrictions imposed by the host’s immunity, in order to prevent the bacterium from spreading from the nasopharynx to other tissues, such as the brain. Some authors claim that strains of S. pneumoniae, which fail to survive in the bloodstream, can enter the brain directly from the nasal cavity by axonal transport through the olfactory and/or trigeminal nerves. However, from the immunological point of view, glial cells are far more responsive to bacterial infections than are neurons. This hypothesis is consistent with several recent reports showing that bacteria can infect glial cells from the olfactory bulb and trigeminal ganglia. Since our group previously demonstrated that Schwann cells (SCs) express a functional and appropriately regulated mannose receptor (MR), we decided to test whether SCs are involved in the internalization of S. pneumoniae via MR.